The Latest
-
Permission granted by Laurie Stelzer Mirati
Podcast
Woman of the Week: Mirati Therapeutics’ Laurie Stelzer
With the recent approval of Krazati, the biotech veteran is guiding Mirati into its next phase as a commercial organization.
-
Scott Olson via Getty Images
CVS is exiting clinical trials. Does this spell trouble for retail-based research?
Walgreens leaders are not deterred and hope to fill the holes left behind by the pharmacy giant.
-
Anna Moneymaker/Staff via Getty Images
3 FDA decisions that could be delayed if the U.S. defaults on its debt
If federal lawmakers don’t vote to raise the debt limit by early June, these FDA actions could be impacted.
-
Permission granted by Rashmi Gupta Microsoft
OpinionThe ‘superpowers’ pharma leaders should cultivate
Executives honored by the Healthcare Businesswomen’s Association share the key traits that help them drive results.
-
Carol Highsmith. (2005). "The Apex Building" [Photo]. Retrieved from Wikimedia Commons.
From FTC to SCOTUS, Amgen’s woes are potential ‘game changers’ for the industry
The two institutional battles offer a glimpse into the tension between pharma innovation and regulation that could reverberate across the industry.
-
Stock via Getty Images
The cell ‘atlasing’ approach pushing the limits of drug discovery
Vizgen’s CEO discusses the potential of spatial genomics in the life sciences and the company’s role in the movement.
-
Permission granted by Lisa Ricciardi Cognition Therapeutics
Podcast
Woman of the Week: Cognition Therapeutics’ Lisa Ricciardi
As CEO of the neurogenerative company, Ricciardi is applying her decades of “human capital” to advance Alzheimer’s and dementia treatments.
-
Stock via Getty Images
Biotechs blast experiments into space
Conducting life sciences research in space’s microgravity could have far-ranging implications for drug development on Earth.
-
iStock via Getty Images
The power of genetics — how research into gene sequencing could revolutionize biopharma
Ancient DNA from a deer tooth. A new way to connect genes with disease. Biological super-computing. These genetic advances could play a part in our biopharma future.
-
Stock via Getty Images
Strangers in a strange land: 8 unlikely companies making plays in pharma
How these consumer and service companies are tapping into major trends in the biopharma industry.
-
Stock via Getty Images
Amid surging Duchenne market, Capricor touts potential ‘backbone’ therapy of the space
The company's CEO on the vital role its late-stage candidate could play in the lives of DMD patients.
-
Stock via Getty Images
OpinionHow biopharma executives fight burnout
Pharma leaders share what they do to keep their teams from fizzling out.
-
(2021). Retrieved from NCI.
Making MovesBiden’s pick to lead the NIH faces an uphill battle
Pending Senate confirmation, NCI head Monica Bertagnolli will take the helm of the collection of research organizations as it faces increasing bipartisan scrutiny.
-
Stock via Getty Images
OpinionWhat pharma can teach biotech about the life cycle management of a drug
Global product teams are common in pharma but have yet to gain traction in biotech. Here's why this model can work.
-
Permission granted by Patricia Hurter
ProfileA day in the life of a pharma exec: Lyndra’s Patricia Hurter
How the CEO starts each day with a ride on one of her horses, reduces daily meetings and uses her network to get through crises like the SVB Bank collapse.
-
Permission granted by Veronica Sandoval
Podcast
Woman of the Week: Genentech’s Veronica Sandoval
How the Genentech diversity exec is using ‘three Ms’ to reduce health disparities and improve access for under-supported communities.
-
Stock via Getty Images
Q&AFrom farm to pharma: How cows could play a role in the next flu breakthrough
SAb Biotherapeutics is working on a novel product that uses cow antibodies genetically engineered into human antibodies to prevent and treat infectious diseases.
-
artJazz via Getty Images
Major regulatory changes are coming to pharma in the EU — and industry’s weighing in
The European Union published a long-awaited proposal that could bring sweeping changes to its pharma sector last month, but the legislative fight has only just begun.
-
Stock via Getty Images
Years into the pandemic, only a handful of clinical trials are targeting long COVID — here’s one of them
Scientists at Stanford are testing Pfizer’s Paxlovid on long COVID symptoms and their efforts could provide clues for other conditions.
-
Stock via Getty Images
How pharma’s rocky real estate market has changed — for better and worse
Whether you’re looking to build a new site or expand lab space, here are the biggest trends impacting life sciences real estate.
-
Permission granted by Christopher Boone AbbVie
Q&AAbbVie’s Christopher Boone on RWE’s potential — and its ‘profound ethical dilemmas’
With decades of experience in public health, Boone is leveraging RWE to move the needle within clinical development.
-
Permission granted by Ashley Hall Reneo Pharmaceuticals
Podcast
Woman of the Week: Reneo Pharmaceuticals’ Ashley Hall
After ushering a blockbuster to market, the chief development officer is channeling her experience into the rare disease space.
-
Permission granted by Daniela Marino
ProfileThis ‘hot-blooded’ CEO is aiming to transform the way burn victims heal
Cutiss CEO Daniela Marino is funneling her bold personality and expertise in regenerative medicine into a startup developing bioengineered skin grafts.
-
iStock via Getty Images
Led by the Pfizer-Seagen deal, ADCs are starting to ‘take center stage’
Antibody-drug conjugates got a major boost with the megamerger of Pfizer and Seagen, and experts believe they will continue to be an important catalyst in biopharma.
-
Stock via Getty Images
3 key FDA approval trends this year
Although approvals are off to a slow start in oncology, the agency has been living in the fast lane for neurological disorders and more.
